Webinars

Webinar Session #1: Real World Evidence and Real World Data (Intro)

• Time: Nov 5, 2-4 PM EDT.
• Confirmed Speakers:
  • L. J. Wei (Harvard University)
    Practical Experience in Utilizing Real-World and Clinical Trial Data for Assessing Treatment Effects (slides)
  • Jane White (Pfizer)
    Designing a Registrational Study with Real World Data as a Synthetic Control Arm (slides)
  • Jian Zhu (Servier)
    Bayesian Divide-and-Conquer Propensity Score Based Approaches for Leveraging Real World Data in Single Arm Clinical Trials (slides)
• Recording: https://pfizerevents.webex.com/pfizerevents/lsr.php?RCID=5256e81f345b8e5989fd8ffd0aec58f0

Webinar Session #2: Master Protocols

• Time: Nov 12, 2-4 PM EST.
• Confirmed Speakers:
  • Anne Heatherington (Takeda)
    Data, Digital and the Future of Drug Development (Tentative)
  • Donald Berry (M.D. Anderson)
    Master Protocols for Rare Diseases: Baskets and Platforms (slides)
  • Jianchang Lin (Takeda)
    Statistical Considerations for Clinical Trials with Multiple Indications (slides)
• Recording: https://nerds.nestat.org/session2-recording.html

Webinar Session #3: External/Historical Data

• Time: Nov 19, 2-4 PM EST.
• Confirmed Speakers:
  • Jeff Barrett (C-Path)
    Rare Disease Cures Accelerator–Data and Analytics Platform: Opportunities for Statistical Collaborations (slides)
  • Ruthie Davi (Acorn AI)
    Use of External or Synthetic Control in the Development of a Treatment for Recurrent Glioblastoma (slides)
  • Veronica Bunn (Takeda)
    Propensity-Score-Based Meta-Analytic Predictive Prior for Incorporating Real-World and Historical Data (slides)
  • Chenghao Chu (Vertex)
    Dynamic Historical Data Borrowing Using Weighted Average (slides)
• Recording: https://pfizerevents.webex.com/pfizerevents/lsr.php?RCID=9751f999b6e7501612d45d58f3112b80

Webinar Session #4: Composite Endpoints

• Time: Dec 3, 2-4 PM EST.
• Confirmed Speakers:
  • Marc Buyse (IDDI and CluePoints)
    Generalized Pairwise Comparisons for Rare Diseases (slides)
  • Yan Wang (FDA)
    Global Tests for Multiple Endpoints in Rare Disease Clinical Trials (slides)
  • Glen Laird and Xiaoyan Liu (Vertex)
    Combining Mixed Endpoint Types for Totality of Evidence Analyses (slides)
• Recording: https://pfizerevents.webex.com/pfizerevents/lsr.php?RCID=f643a5bf06e05a2ebfcbc5856e82535e